{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:29:13Z","timestamp":1795051753289,"version":"4.10.2"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","award":["Uncondional donation"],"award-info":[{"award-number":["Uncondional donation"]}],"id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"name":"COVIM NaFoUniMedCovid19","award":["Not applicable, consortium, finanical support"],"award-info":[{"award-number":["Not applicable, consortium, finanical support"]}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","award":["Uncondional donation"],"award-info":[{"award-number":["Uncondional donation"]}],"id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Freunde und F\u00f6rderer der Berliner Charit\u00e9","award":["Uncondional donation"],"award-info":[{"award-number":["Uncondional donation"]}]},{"DOI":"10.13039\/100017596","name":"Federal Institute for Drugs and Medical Devices","doi-asserted-by":"crossref","award":["01KX2021"],"award-info":[{"award-number":["01KX2021"]}],"id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017596","name":"Federal Institute for Drugs and Medical Devices","doi-asserted-by":"crossref","award":["V-2021.3 \/ 1503_68403 \/ 2021-2022"],"award-info":[{"award-number":["V-2021.3 \/ 1503_68403 \/ 2021-2022"]}],"id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1310 and SFB-TR84"],"award-info":[{"award-number":["CRC1310 and SFB-TR84"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"crossref","award":["Not applicable, consortium, financial support"],"award-info":[{"award-number":["Not applicable, consortium, financial support"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,9,12]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67\u201373 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20\u201323 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after\u2014not before\u2014was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1\u2009week MTX break is sufficient if the last administration of MTX occurs 1\u20133\u2009days before vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002639","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:19:40Z","timestamp":1665404380000},"page":"e002639","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct05313061","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-4746","authenticated-orcid":false,"given":"Elisa","family":"Habermann","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-3318","authenticated-orcid":false,"given":"Lutz","family":"Gieselmann","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virologie, University Hospital Cologne, 50931 Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany"},{"name":"Partner site Bonn-Cologne, German Centre for Infection Research, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-3663","authenticated-orcid":false,"given":"Pinkus","family":"Tober-Lau","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-5755","authenticated-orcid":false,"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-9080","authenticated-orcid":false,"given":"Fredrik Nils","family":"Albach","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8657-8019","authenticated-orcid":false,"given":"Alexander","family":"ten Hagen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-2177","authenticated-orcid":false,"given":"Jan","family":"Zernicke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin","family":"Ahmadov","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virologie, University Hospital Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-9747","authenticated-orcid":false,"given":"Amanthi Nadira","family":"Arumahandi de Silva","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-9190","authenticated-orcid":false,"given":"Leonie Maria","family":"Frommert","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-473X","authenticated-orcid":false,"given":"Florian","family":"Kurth","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-9947","authenticated-orcid":false,"given":"Leif Erik","family":"Sander","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1792","authenticated-orcid":false,"given":"Florian","family":"Klein","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virologie, University Hospital Cologne, 50931 Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany"},{"name":"Partner site Bonn-Cologne, German Centre for Infection Research, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2025090312484043000_8.2.e002639.1","unstructured":"Ritchie H , Mathieu E , Rod\u00e9s-Guirao L . Coronavirus pandemic (COVID-19). Our world in data. Available: https:\/\/ourworldindata.org\/coronavirus [Accessed 5 March 2020]."},{"key":"2025090312484043000_8.2.e002639.2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1126\/science.abn4543","article-title":"Track omicron's spread with molecular data","volume":"374","author":"Scott","year":"2021","journal-title":"Science"},{"key":"2025090312484043000_8.2.e002639.3","unstructured":"Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant - PubMed. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/35042228\/ [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat Med"},{"key":"2025090312484043000_8.2.e002639.5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"2025090312484043000_8.2.e002639.6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090312484043000_8.2.e002639.7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090312484043000_8.2.e002639.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119451"},{"key":"2025090312484043000_8.2.e002639.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3685"},{"key":"2025090312484043000_8.2.e002639.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.854"},{"key":"2025090312484043000_8.2.e002639.11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.42058","article-title":"Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases","volume":"74","author":"Bitoun","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090312484043000_8.2.e002639.12","unstructured":"Kane S . Methotrexate - Drug Usage Statistics, ClinCalc DrugStats Database.. Available: https:\/\/clincalc.com\/DrugStats\/Drugs\/Methotrexate [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.269"},{"key":"2025090312484043000_8.2.e002639.14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/art.42153","article-title":"Immunogenicity and safety of standard and Third-Dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy","volume":"74","author":"Syversen","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090312484043000_8.2.e002639.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221876"},{"key":"2025090312484043000_8.2.e002639.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221916"},{"key":"2025090312484043000_8.2.e002639.17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","article-title":"Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial","volume":"10","author":"Abhishek","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025090312484043000_8.2.e002639.18","doi-asserted-by":"crossref","unstructured":"Aikawa NE . Kupa L de VK, Medeiros-Ribeiro AC, et al. increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis 2022.","DOI":"10.1136\/annrheumdis-2021-222096"},{"key":"2025090312484043000_8.2.e002639.19","unstructured":"Nhs England and NHS improvement North West \u00bb advice for those who are severely immunosuppressed around COVID-19 vaccine doses.. Available: https:\/\/www.england.nhs.uk\/north-west\/covid-19-vaccination-information\/advice-for-those-who-are-severely-immunosuppressed-around-covid-19-vaccine-doses\/ [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.20","unstructured":"RKI - Infektionskrankheiten A-Z - STIKO-Empfehlung zur COVID-19-Impfung.. Available: https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/ImpfungenAZ\/COVID-19\/Impfempfehlung-Zusfassung.html;jsessionid=CCB27383ED733194F303D97328155211.internet082?nn=2386228 [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.21","unstructured":"COVID-19 Vaccination CDC . Centers for disease control and prevention, 2020. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.22","unstructured":"COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines . European centre for disease prevention and control., 2022. Available: https:\/\/www.ecdc.europa.eu\/en\/news-events\/ema-ecdc-statement-fourth-covid-vaccine-dose [Accessed 23 May 2022]."},{"key":"2025090312484043000_8.2.e002639.23","doi-asserted-by":"crossref","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"2025090312484043000_8.2.e002639.24","unstructured":"Huh J , Carriere KC . Estimation of regression functions with a discontinuity in a derivative with local polynomial %ts."},{"key":"2025090312484043000_8.2.e002639.25","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312484043000_8.2.e002639.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211128"},{"key":"2025090312484043000_8.2.e002639.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221735"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:48:52Z","timestamp":1756928932000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,10]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/rmdopen-2022-002639"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002639","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.11.22276272","asserted-by":"object"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}